Skip to main content
View expanded cover

Management of Heart Failure pp 277–286Cite as

Review of Heart Failure Management in African-Americans

  • Chapter

Abstract

Heart disease remains the leading cause of death in African-Americans. Heart failure contributes to this mortality rate and has changed minimally over the years, persisting at rates above Caucasians. In fact, the rates of re-hospitalization associated with heart failure continue to rise particularly among African-Americans. Current estimations reveal that the heart failure prevalence in African-Americans is 3 %, and the risk of developing heart failure is the highest in this population. Despite the abundance of evidence based therapies for heart failure management, several studies have documented that many African-American heart failure patients do not receive adequate treatment. We will review the evidence-based treatment of heart failure in African-Americans.

Keywords

  • Heart failure
  • Blacks
  • Hypertension
  • Nitrates
  • Hydralazine
  • A-HeFT
  • Beta blockers
  • Renin-angiotensin
  • Guidelines
  • AICD
  • Hypertrophy

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4471-6657-3_14
  • Chapter length: 10 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-1-4471-6657-3
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   179.00
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 14.1
Fig. 14.2
Fig. 14.3
Fig. 14.4
Fig. 14.5

References

  1. (OMHHE) CO of MH & HE. CDC – black – African American – populations – racial – ethnic – minorities – minority health. Available at: http://www.cdc.gov/minorityhealth/populations/REMP/black.html. Accessed 6 Feb 2013.

  2. Chen J, Normand S, Wang Y, Krumholz H, et al. National and regional trends in heart failure hospitalization and mortality rates for medicare beneficiaries, 1998–2008. JAMA. 2011;306(15):1669–78.

    Google Scholar 

  3. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WHW, Teerlink JR, Walsh MN. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):e1–194.

    CrossRef  PubMed  Google Scholar 

  4. Joynt K, Orav E, Jha A, et al. Thirty-day readmission rates for medicare beneficiaries by race and site of care. JAMA. 2011;305(7):675–81.

    Google Scholar 

  5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62(16):1495–539.

    CrossRef  Google Scholar 

  6. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc. 2002;94(8):666–8.

    PubMed Central  PubMed  Google Scholar 

  7. Franciosa JA, Ferdinand KC, Yancy CW, Consensus Statement on Heart Failure in African Americans Writing Group. Treatment of heart failure in African Americans: a consensus statement. Congest Heart Fail. 2010;16(1):27–38.

    CrossRef  PubMed  Google Scholar 

  8. Yancy CW, Abraham WT, Albert NM, Clare R, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, She L, Sun JL, Young JB, Fonarow GC. Quality of care of and outcomes for African Americans hospitalized with heart failure findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. J Am Coll Cardiol. 2008;51(17):1675–84.

    CrossRef  PubMed  Google Scholar 

  9. Yancy CW. Heart failure in African Americans: unique etiology and pharmacologic treatment responses. J Natl Med Assoc. 2003;95(1):1–12.

    PubMed Central  PubMed  Google Scholar 

  10. Alexander M, Grumbach K, Selby J, Brown A, Washington E, et al. Hospitalization for congestive heart failure: explaining racial differences. JAMA. 1995;274(13):1037–42.

    Google Scholar 

  11. Kannel MD. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5(2):167–73.

    CAS  CrossRef  PubMed  Google Scholar 

  12. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey Jr DE, McMurray JJV, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL, ACCF/AHA Task Force Members. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):1495–539.

    Google Scholar 

  13. Wood AJJ. Racial differences in the response to drugs — pointers to genetic differences. N Engl J Med. 2001;344(18):1394–6.

    CAS  CrossRef  PubMed  Google Scholar 

  14. Small KM, Wagoner LE, Levin AM, Kardia SLR, Liggett SB. Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347(15):1135–42.

    CAS  CrossRef  PubMed  Google Scholar 

  15. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Taylor AL, Cohn JN, Feldman AM, Worcel M. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure results from the a-HeFT Trial. J Am Coll Cardiol. 2006;48(6):1277–82.

    CAS  CrossRef  PubMed  Google Scholar 

  16. Domanski M. A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9(5):354–63.

    CAS  CrossRef  PubMed  Google Scholar 

  17. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–67.

    CrossRef  Google Scholar 

  18. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, Murray D, Oren R, Rosenberg Y, Young J, Zile M, Eichhorn E, Best Investigators. A comparative analysis of the results from 4 trials of -blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9(5):354–63.

    CAS  CrossRef  PubMed  Google Scholar 

  19. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344(18):1358–65.

    CAS  CrossRef  PubMed  Google Scholar 

  20. Eichhorn EJ, Bristow MR. The carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med. 2001;2(1):20–3.

    PubMed Central  CAS  CrossRef  PubMed  Google Scholar 

  21. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.

    Google Scholar 

  22. Kelesidis I, Varughese CJ, Hourani P, Zolty R. Effects of β-adrenergic blockade on left ventricular remodeling among Hispanics and African Americans with chronic heart failure. Clin Cardiol. 2013;36(10):595–602.

    PubMed  Google Scholar 

  23. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting–enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344(18):1351–7.

    CAS  CrossRef  PubMed  Google Scholar 

  24. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.

    Google Scholar 

  25. Cohn JN. V-HeFT I and V-HeFT II Trials―_The Path to A-HeFT. 2005. Available at: www.fda.gov/ohrms/…/2005-4145S2_01_02-NitroMed-V-HeFT.ppt.

  26. Wright JJ. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–31.

    CAS  CrossRef  PubMed  Google Scholar 

  27. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.

    CAS  CrossRef  PubMed  Google Scholar 

  28. Taylor AL. The African American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005;96(7):44–8.

    CrossRef  PubMed  Google Scholar 

  29. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007;115(13):1747–53.

    CAS  CrossRef  PubMed  Google Scholar 

  30. Zannad F, McMurray J, Krum H, Van Veldhuisen D, Swedberg K, Shi H, Vincent J, Pocock S, Pitt B. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N. Engl. J. Med. 2011;364:11–21.

    Google Scholar 

  31. Hernandez A, Fonarow G, Liang L, Al-Khatib S, Curtis L, LaBresh K, Yancy C, Albert N, Peterson E, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298(13):1525–32.

    Google Scholar 

  32. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Poole JE, Lee KL, Bardy GH. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2008;155(3):501–6.

    PubMed Central  CrossRef  PubMed  Google Scholar 

  33. Farmer SA, Kirkpatrick JN, Heidenreich PA, Curtis JP, Wang Y, Groeneveld PW. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm. 2009;6(3):325–31.

    CrossRef  PubMed  Google Scholar 

  34. Elanchenny M, Moss AJ, McNitt S, Aktas M, Polonsky S, Zareba W, Goldenberg I. Effectiveness of cardiac resynchronization therapy with defibrillator in at-risk black and white cardiac patients. Ann Noninvasive Electrocardiol. 2013;18:140–8.

    CrossRef  PubMed  Google Scholar 

  35. Miller LW. Left ventricular assist devices are underutilized response to miller. Circulation. 2011;123(14):1552–8.

    CrossRef  PubMed  Google Scholar 

  36. Aggarwal A, Gupta A, Pappas PS, Tatooles A, Bhat G. Racial differences in patients with left ventricular assist devices. ASAIO J. 2012;58(5):499–502.

    CAS  CrossRef  PubMed  Google Scholar 

  37. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.

    CrossRef  PubMed  Google Scholar 

  38. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.

    CAS  CrossRef  PubMed  Google Scholar 

  39. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, Shinn T, Solomon S, Steinberg JS, Wilber D, Barsheshet A, McNitt S, Zareba W, Klein H. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) clinical perspective. Circulation. 2011;124(14):1527–36.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Division of Cardiology, The Ohio State Wexner Medical Center, 473 West 12th Street; 200 Davis HLRI, Columbus, OH, 43210, USA

    Khadijah Breathett MD

  2. Division of Cardiovascular Medicine, Department of Internal Medicine, Davis Heart & Lung Research Institute, The Ohio State University Wexner Medical Center, 473 W 12th Avenue, #200, Columbus, OH, 43210-1252, USA

    Ragavendra R. Baliga MD, MBA, FACP, FACC, FRCP

  3. Department of Cardiovascular Medicine, The Ohio State University College of Medicine, 370 West 9th Avenue, Columbus, OH, 43210, USA

    Quinn Capers IV

Authors
  1. Khadijah Breathett MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ragavendra R. Baliga MD, MBA, FACP, FACC, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Quinn Capers IV
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Khadijah Breathett MD .

Editor information

Editors and Affiliations

  1. Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA

    Ragavendra R. Baliga

  2. Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Colombus, Ohio, USA

    Garrie J. Haas

Rights and permissions

Reprints and Permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Breathett, K., Baliga, R.R., Capers, Q. (2015). Review of Heart Failure Management in African-Americans. In: Baliga, R., Haas, G. (eds) Management of Heart Failure. Springer, London. https://doi.org/10.1007/978-1-4471-6657-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6657-3_14

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6656-6

  • Online ISBN: 978-1-4471-6657-3

  • eBook Packages: MedicineMedicine (R0)